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ABSTRACT
The research reported in this paper identifies the epigenetic biomarker (methylation beta pattern) of breast cancer. Many
cancers are triggered by abnormal gene expression levels caused by aberrant methylation of CpG sites in the DNA. In order to
develop early diagnostics of cancer-causing methylations and to develop a treatment, it is necessary to identify a few dozen
key cancer-related CpG methylation sites out of the millions of locations in the DNA. This research used public TCGA dataset
to train a TensorFlow machine learning model to classify breast cancer versus non-breast-cancer tissue samples, based on
over 300,000 methylation beta values in each sample. L1 regularization was applied to identify the CpG methylation sites most
important for accurate classification. It was hypothesized that CpG sites with the highest learned model weights correspond to
DNA locations most relevant to breast cancer. A reduced model trained on methylation betas of just the 25 CpG sites having
the highest weights in the full model (trained on methylation betas at over 300,000 CpG sites) has achieved over 94% accuracy
on evaluation data, confirming that the identified 25 CpG sites are indeed a biomarker of breast cancer.
Introduction
Methylation is the addition of methyl groups to nucleotides in the DNA molecule. The effects of methylation are particularly
important at CpG sites, which are regions of DNA where a cytosine nucleotide is followed by a guanine nucleotide. When
a cytosine nucleotide at a CpG site in a promoter region of DNA is methylated, the resulting effect is downregulation of the
expression of the respective gene. Methylation can occur at millions of CpG sites throughout the DNA. The CpG sites can be
both overmethylated and undermethylated compared to normal levels1, 2.
Abnormalities in DNA methylation are important causes of development and progression of cancer1–6. Indeed, aberrations
in methylation levels often appear well before the cancer develops, even while the cells still look completely normal under the
microscope6, 7.
In cancers, it is common that CpG sites are over-methylated at genes that make proteins promoting tumor suppressor
genes3, 6, 8, 9, DNA repair genes7, 10, and genes that control cell cycle, differentiation, and apoptosis11. This results in silencing
of tumor suppression and DNA repair, which contributes to development of cancer via an increased occurrence of unrepaired
gene mutations and runaway cancer cells2. The silencing of tumor suppressor genes by abnormal over-methylation is in fact
much more frequent than their inactivation by DNA mutations12.
At the same time, CpG sites in cancer are often under-methylated at oncogenes, which can cause tumors when overex-
pressed6. Genome-wide average methylation levels are also significantly lower in tumors than in healthy cells, and are still
lower in metastatic cancer cells3, 8, 9.
The presence of both hypo- and hyper-methylation in cancer cells means that effective pharmaceutical treatments will have
to be able to correct dangerous methylation levels in both directions: decrease methylation at CpG sites where abnormally
high methylation is harmful, and increase at sites where abnormally low methylation is harmful. Methylation abnormalities
are reversible3, and there are indeed pharmaceuticals approved by the FDA that can be used to reduce methylation levels
genome-wide4, 6, 13–15. They are used to treat precancerous conditions and certain cancers caused by over-methylation of tumor
suppressor genes. However, those medications have side effects and may cause other cancers by increasing expression of
oncogenes and genes that promote cell invasiveness, and by causing general instability of the genome via broad upregulation of
gene expressions14, 16.
Several years ago, CRISPR technology was developed to correct genetic abnormalities at precise locations in the DNA17.
It is plausible that in another several years a technology will be developed to correct epigenetic abnormalities at precisely
specified CpG methylation sites. In order to be able to apply this technology for prevention and treatment of cancer, it will be
necessary to know exactly which CpG methylation sites to correct, and in which direction to change the methylation, out of
the hundreds of thousands of CpG sites in the DNA whose methylation can be measured with currently available sequencing
technologies.
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This research identifies the key CpG sites in the DNA whose methylation levels comprise the biomarker (epigenetic
signature) of breast cancer, and which can be used to identify, with high accuracy, breast cancer tissue samples among tissue
samples of various other types of cancer.
Results and Discussion
This research has identified 25 CpG locations in the DNA whose methylation beta patterns are sufficient to classify breast
cancer vs. non-breast-cancer solid tissue samples with a 94.6% accuracy using a machine learning classification model trained
on methylation beta values at those 25 locations (Figure 4).
This represents only a modest drop from the 98.6% accuracy on evaluation data in the breast cancer vs. non-breast-cancer
classification model trained on the full set of 323,179 CpG sites (Figure 3). The retention of most of the accuracy indicates
that the methylation beta patterns at the identified 25 CpG sites are, indeed, a biomarker of breast cancer and can be used to
distinguish it from other types of cancer with high accuracy.
Nine of the genes containing the identified 25 CpG sites ( TAF3, SFRP4, SBDS, PPP2R2A, RASSF4, MTA2, ZNF135,
CDHR2, PACS2) turn out to be directly involved in the cell cycle and to regulate cell growth, differentiation, division, apoptosis,
and tumor suppression (Table 1). These findings further confirm the significance of the CpG methylation sites identified by this
research as an epigenetic biomarker of breast cancer.
Several of the genes containing the identified 25 CpG sites have unknown functions as of yet, and could turn out to regulate
tumor-related activities as well. Their role in breast cancer is yet to be determined, and presents a direction for future research.
The mean methylation beta values for the 25 CpG sites, for the breast-cancer and non-breast-cancer solid tissue samples,
are shown in Table 2.
The methodology applied in this research can be extended to identify epigenetic biomarkers for types of cancer other than
breast cancer (the BRCA study in TCGA). Another direction for future research is to learn epigenetic biomarkers shared by
multiple cancer types, by training a machine learning model to classify cancerous vs. normal tissues.
The knowledge of the epigenetic signature of breast cancer identified in this research is valuable in several ways: it can
enable development of medications to correct abnormal methylation at precisely the CpG sites that control expression of genes
involved in the development and progression of cancer, and it can also be used for early diagnostics and prevention of breast
cancer, at the stage where analysis of tissue cells under the microscope (in biopsies) doesn’t show any abnormalities, yet the
epigenetic signature of cancer is already present.
Materials and Methods
The research reported in this paper was performed using data in the public DNA methylation betas dataset18 produced by The
Cancer Genome Atlas Program19, containing tissue samples from 32 different types of cancer. The data has been retrieved
from the public dataset isb-cgc:TCGA_hg38_data_v0, hosted by the Institute for Systems Biology - Cancer Genomics Cloud
(ISB-CGC)20 project on Google Cloud21. The data has been accessed via Google BigQuery22. Methylation betas for more
than 400,000 CpG sites in 8,703 solid cancer tissue samples (identified by unique aliquot barcodes) were retrieved from the
TCGA_hg38_data_v0.DNA_Methylation table.
A subset of samples and CpG probes were selected for use in the project, such that each included sample would contain
methylation betas for the same set of CpG probes. This step reduced the size of the research dataset to 8,126 aliquots, with the
same 323,179 probes included with each aliquot.
In the next step, training examples were constructed for the machine learning classification model, with each training
example comprising a list of 323,179 methylation beta values for one aliquot, as the input features of the model. For each
training example, the label was set to 1 for aliquots derived from BRCA (breast cancer study) tissue samples, and 0 for aliquots
from all other included TCGA cancer studies. In order to prevent the classification model from being biased towards 1 or 0
values of the label, the same number of training examples were constructed for BRCA as for all other (non-BRCA) studies
combined. Within the non-BRCA class (comprising training examples with the label 0), the same number of training examples
were constructed from aliquots in each included non-BRCA study. The number of solid cancer tissue samples (aliquots)
available for each cancer study in the TCGA dataset ranges from 763 for BRCA (breast cancer study) to 10 for OV. Altogether,
training examples were generated using aliquots from the 22 TCGA studies having the highest number of available tissue
samples.
In the following step, a classification model was trained using the tf.estimator.DNNClassifier class available in the
TensorFlow23 machine learning library. The classifier has been configured with one fully connected layer containing 128
hidden units, and two classes (1 or 0) corresponding to training examples as being either BRCA or non-BRCA. The Proximal
Adagrad optimizer (available as the tf.train.ProximalAdagradOptimizer class in TensorFlow) was used to train the model with
L1 regularization enabled. The regularization level was set to 0.005 to force the model to use as few input features as possible
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without significantly hurting the accuracy of classification. The goal in using L1 regularization was to identify CpG sites in
the genome whose methylation beta values are the most indispensable for the model for accurate classification of training
examples. The model was trained using 80% of all training examples constructed in the previous step, with the remaining 20%
of examples held out for the evaluation of results. Upon completion of 30,000 training steps, 98.7% of weights in the model’s
fully connected layer had the value of zero (Figure 1).
In the next step, the CpG sites (probe IDs) were sorted by the sums of absolute values of their weights in the classification
model’s fully connected layer (Figure 2), and the 25 CpG probe IDs with the highest model weights were selected.
A new classification model was then trained using the same 80% of training examples as in the original model but with
each example constrained to include methylation betas of the selected top 25 probe IDs only (instead of the 323,179 betas
used to train the first model). The same 20% of examples (constrained to the top 25 probe IDs) were used for the evaluation of
the model. The training of the second model was configured with the same settings as in the first model, except that this time
regularization was not applied. The purpose of the second model was to verify that the selected top 25 probes are indeed the
key CpG sites comprising the biomarker of breast cancer.
Upon completion of model training, the data in the isb-cgc:platform_reference.GDC_hg38_methylation_annotation table
in BigQuery was used to identify the genes containing the model-selected top 25 CpG sites. The GeneCards24 and OMIM25
databases were then used to look up the functions of those genes.
Finally, the average methylation beta values were computed for the selected top 25 CpG sites, for BRCA and non-BRCA
tissue samples in TCGA.
Data Availability
The Cancer Genome Atlas data analysed during the current study is available in the public BigQuery dataset repository
isb-cgc:TCGA_hg38_data_v0 in Google Cloud, at https://bigquery.cloud.google.com/dataset/isb-cgc:
TCGA_hg38_data_v0.
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Figure 1. Fraction of zero weights in the classification model using methylation betas for 323,179 distinct CpG probe IDs.
The horizontal axis shows the number of training steps completed by the model.
Figure 2. Sum of the absolute values of model weights for each CpG probe ID. The chart includes the top 1,000 probe IDs
(out of 323,179 probe IDs used to train the first classification model), ordered by the sum of absolute values of weights, in
descending order. The weights of the top 25 CpG sites are much higher than the weights of the remaining probes.
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CpG probe ID Chromosome Position Gene symbol Function of the gene
cg24525395 chr2 60569992 N/A To be determined.
cg14371620 chr2 118182593 AC093901.1 To be determined.
cg06282247 chr2 150425327 N/A To be determined.
cg16171484 chr2 222425796 SGPP2 To be determined.
cg00332146 chr5 176548900 CDHR2 Involved in tumor suppression, inhibition of cell
proliferation.
cg00332146 chr5 176548900 RN7SL684P To be determined.
cg27064266 chr6 27865624 HIST1H2AL To be determined.
cg27064266 chr6 27865624 HIST1H2BN To be determined.
cg27064266 chr6 27865624 HIST1H2BPS2 To be determined.
cg27064266 chr6 27865624 Z98744.2 To be determined.
cg02335619 chr6 31835168 C6orf48 To be determined.
cg02335619 chr6 31835168 SNORD48 To be determined.
cg06962768 chr7 37920180 EPDR1 To be determined.
cg06962768 chr7 37920180 SFRP4 Involved in apoptosis and regulation of cell growth
and differentiation.
cg00498438 chr7 66995689 SBDS Affects apoptosis.
cg00498438 chr7 66995689 TYW1 To be determined.
cg22274662 chr7 149497004 ZNF746 To be determined.
cg13877285 chr8 26291357 PPP2R2A Negative control of cell growth and division.
cg04693895 chr10 385155 DIP2C To be determined.
cg12777293 chr10 7818591 TAF3 Acts as an antiapoptotic factor.
cg27139956 chr10 44974842 C10orf10 To be determined.
cg27139956 chr10 44974842 RASSF4 Tumor suppression. Promotes apoptosis and cell
cycle arrest. Inhibits tumor cell growth and colony
formation. Broadly expressed in normal cells, down-
regulated by methylation in tumor cells.
cg13298116 chr11 62602387 EML3 To be determined.
cg13298116 chr11 62602387 MTA2 Associated with metastasis of cancer cells. Regu-
lates gene expression. Is overexpressed in cancers.
Correlates with cancer invasiveness and aggressive-
ness. Overexpression of MTA2 promotes metastasis
of breast cancer cells. Regulates pathways involved
in regulation, apoptosis, growth of normal and can-
cer cells.
cg14100748 chr14 90577405 TTC7B To be determined.
cg12158535 chr14 105390913 PACS2 Involved in cell apoptosis.
cg01027010 chr16 31565018 CTD-2014E2.5 To be determined.
cg00103783 chr17 7583931 AC113189.5 To be determined.
cg00103783 chr17 7583931 MPDU1 To be determined.
cg14204735 chr17 63446943 CYB561 To be determined.
cg15751406 chr19 8823867 CTD-2529P6.3 To be determined.
cg15751406 chr19 8823867 ZNF558 To be determined.
cg09907936 chr19 58059098 ZNF135 Involved in both normal and abnormal cellular pro-
liferation and differentiation.
cg23060618 chr21 43301197 N/A To be determined.
cg03113871 chr22 30921800 MORC2-AS1 To be determined.
cg20180585 chr22 41381751 TEF To be determined.
Table 1. Mapping of the top 25 CpG sites identified by the model to chromosome positions, genes, and respective gene
functions, based on the GeneCards and OMIM databases. Nine of the genes are directly involved in the cell cycle and
regulation of cell growth, differentiation, division, apoptosis, and tumor suppression. The function of the remaining genes is yet
to be determined.
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CpG probe ID non-BRCA beta mean BRCA beta mean
cg03113871 0.146 0.105
cg24525395 0.153 0.161
cg16171484 0.542 0.734
cg14100748 0.888 0.899
cg00103783 0.024 0.022
cg22274662 0.042 0.042
cg20180585 0.013 0.012
cg27139956 0.158 0.09
cg13877285 0.029 0.022
cg04693895 0.931 0.958
cg23060618 0.742 0.778
cg12158535 0.682 0.667
cg00498438 0.019 0.019
cg15751406 0.93 0.95
cg01027010 0.604 0.447
cg02335619 0.039 0.036
cg00332146 0.576 0.699
cg14204735 0.204 0.053
cg12777293 0.014 0.013
cg13298116 0.143 0.092
cg06962768 0.759 0.695
cg27064266 0.132 0.122
cg14371620 0.785 0.783
cg09907936 0.344 0.191
cg06282247 0.48 0.625
Table 2. Mean methylation betas for the top 25 model-selected CpG probe IDs, for the BRCA (breast cancer) and non-BRCA
solid tissue samples.
Figure 3. Accuracy of the classification model using methylation betas for 323,179 distinct CpG probe IDs. Accuracy was
computed on the evaluation data (which was not used in training the model). The horizontal axis shows the number of training
steps completed by the model. Accuracy increased during the first several thousand training steps and stabilized around 98.6%.
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Figure 4. Accuracy of the second classification model trained on methylation betas of 25 CpG probes having the highest
weights in the first model. Accuracy was computed on the evaluation data (which was not used in training the model). The
horizontal axis shows the number of training steps completed by the model. Accuracy increased during the first forty million
steps and stabilized around 94.6%.
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